Search Results - "Naumovski, Allison"

RAGE Enhances TLR Responses through Binding and Internalization of RNA by Bertheloot, Damien, Naumovski, Allison L, Langhoff, Pia, Horvath, Gabor L, Jin, Tengchuan, Xiao, Tsan Sam, Garbi, Natalio, Agrawal, Sudhir, Kolbeck, Roland, Latz, Eicke

“…Nucleic acid recognition is an important mechanism that enables the innate immune system to detect microbial infection and tissue damage. To minimize the…”
Get full text

Case report of fatal immune-mediated myocarditis following treatment with davoceticept (ALPN-202), a PD-L1-dependent CD28 costimulator and dual PD-L1/CTLA-4 checkpoint inhibitor, in combination with pembrolizumab by Cavalcante, Ludimila, Chandana, Sreenivasa, Lakhani, Nehal, Enstrom, Amanda, LeBlanc, Heidi, Schmalz, Joseph, Lengyel, Krisztina, Schneider, Frank, Thomas, Heather, Chisamore, Michael J, Peng, Stanford L, Naumovski, Allison, Davar, Diwakar

“…Engagement of programmed death-1 (PD-1) and cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) can interfere with the CD28 signaling requisite for T-cell…”
Get full text

Phase I studies of davoceticept (ALPN-202), a PD-L1-dependent CD28 co-stimulator and dual PD-L1/CTLA-4 inhibitor, as monotherapy and in combination with pembrolizumab in advanced solid tumors (NEON-1 and NEON-2) by Davar, Diwakar, Cavalcante, Ludimila, Lakhani, Nehal, Moser, Justin, Millward, Michael, McKean, Meredith, Voskoboynik, Mark, Sanborn, Rachel E, Grewal, Jaspreet S, Narayan, Ajita, Patnaik, Amita, Gainor, Justin F, Sznol, Mario, Enstrom, Amanda, Blanchfield, Lori, LeBlanc, Heidi, Thomas, Heather, Chisamore, Michael J, Peng, Stanford L, Naumovski, Allison

“…BackgroundDavoceticept (ALPN-202) is an Fc fusion of a CD80 variant immunoglobulin domain designed to mediate programmed death-ligand 1 (PD-L1)-dependent CD28…”
Get full text

Initial Report of Povetacicept, an Enhanced Dual BAFF/APRIL Antagonist, in Autoimmune Cytopenias: The RUBY-4 Study by Broome, Catherine, Kuter, David J, McCrae, Keith R., Davies, Rupert, Enstrom, Amanda, Chunyk, Allison, Thomas, Heather, Naumovski, Allison, Lentz, Steven R.

“…Introduction: BAFF and APRIL are cytokines with key roles in B cell development, survival, differentiation into antibody-secreting cells (ASCs; plasmablasts…”
Get full text

Abstract 1727: Tumor associated macrophages and resistance to immune checkpoint blockade: consideration of cancer indications for the clinical development of JTX-8064, an anti-LILRB2/ILT4 monoclonal antibody by McGrath, Lara, Mueller, Amy, Rahman, Tanzila, Smith, Jeffrey, Yore, Mark, Stack, Edward, O'Malley, Kristin, Dunn, Andrew, Legendre, Kristen, Shenwai, Reva, Willer, Margaret, Naumovski, Allison, Baeck, Johan, Umiker, Ben

“…Leukocyte immunoglobulin-like receptor B2 (LILRB2; ILT4) is expressed on myeloid cells and inhibits myeloid cell activation through binding Major…”
Get full text

Phase 1, first-in-human trial of JTX-8064, an anti-LILRB2/ILT4 monoclonal antibody, as monotherapy and in combination with anti-PD-1 in adult patients with advanced solid tumors (INNATE) by Papadopoulos, Kyriakos P., Lakhani, Nehal J., Yap, Timothy A., Naumovski, Allison L, Brown, Karen S, Umiker, Ben, McGrath, Lara, Zhang, Weidong, Stack, Edward, Riley, Gosia, Mota, Nancy, Tasillo, Christina, Laken, Haley, Trehu, Elizabeth G., Baeck, Johan

“…Abstract only TPS2672 Background: Leukocyte Immunoglobulin-like receptor B2 [LILRB2; immunoglobulin-like transcript 4 (ILT4)] is an immunoinhibitory protein…”
Get full text

738 Interim dose escalation of davoceticept, a conditional CD28 costimulator and dual checkpoint inhibitor, in combination with pembrolizumab in advanced malignancies (NEON-2) by Lakhani, Nehal, Patnaik, Amita, McKean, Meredith, Gainor, Justin, Cathy Vo Buu, Enstrom, Amanda, Davies, Rupert, Dillon, Stacey, Zayed, Hany, Chisamore, Michael, Pluda, James Michael, Naumovski, Allison, Stanford, Peng

“…BackgroundPD-1/PD-L1 inhibitors (PD-(L)1i) have improved outcomes for many patients with advanced malignancies; however, most do not respond, or fail to…”
Get full text